Chad Robins - Adaptive Biotechnologies President CEO, Co-Founder
| ADPT Stock | USD 2.60 0.02 0.78% |
CEO
Mr. Chad Robins is a President, Chief Executive Officer, CoFounder of the Company. He has held executive level positions across multiple industries, including banking, real estate, investing and biotechnology. Prior to Adaptive, Mr. Robins was the VicePresident of Operations for Pulte Homes, and Chief Operating Officer for Connaught Real Estate Finance, an opportunistic hedge fund. He also opened the West Coast office of Wasserstein Perellas software and internet services group then ran business development for HealthAxis.com, an online health insurance company. In 2012, Mr. Robins was a 40 Under 40 Seattle Leaders honoree. While in college and looking for a way to combine his adventuresome spirit with a vast learning opportunity, he spent 100 days in the wilderness with the National Outdoor Leadership School where he gained his open and interactive leadership style along with his strong teamwork mentality. A Cornell University honors graduate with a major in entrepreneurship and business, Mr. Robins obtained his MBA from The Wharton School at the University of Pennsylvania with a major in finance and concentrations in marketing and operations. In addition to the Adaptive Biotechnologies board, Mr. Robins holds board positions for the American Heart Association and Aortica Corporationrationration.
| Professional Marks | MBA |
| Address | 1165 Eastlake Avenue East, Seattle, WA, United States, 98109 |
| Phone | 206 659 0067 |
| Web | https://www.adaptivebiotech.com |
Adaptive Biotechnologies Management Efficiency
The company has return on total asset (ROA) of (0.166) % which means that it has lost $0.166 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5834) %, meaning that it created substantial loss on money invested by shareholders. Adaptive Biotechnologies' management efficiency ratios could be used to measure how well Adaptive Biotechnologies manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.44 in 2024. Return On Capital Employed is likely to drop to -0.37 in 2024. At this time, Adaptive Biotechnologies' Liabilities And Stockholders Equity is comparatively stable compared to the past year. Non Current Liabilities Total is likely to gain to about 276.3 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 84.7 M in 2024.Similar Executives
| Found 10 records | CEO Age | ||
| Larry Dillaha | Royalty PharmaPlc | 52 | |
| Robert Foster | Hepion Pharmaceuticals | N/A | |
| Steven MD | Sana Biotechnology | 54 | |
| Gregory Flesher | Reneo Pharmaceuticals | 54 | |
| Mark Manfredi | Ikena Oncology | 53 | |
| Geoffrey MacKay | AVROBIO | N/A | |
| MBA MSc | Vir Biotechnology | 54 | |
| Cedric Francois | Apellis Pharmaceuticals | 45 | |
| Joseph Podolski | Royalty PharmaPlc | 66 | |
| Geoff MacKay | AVROBIO | 50 | |
Management Performance
| Return On Equity | -0.58 | ||||
| Return On Asset | -0.17 |
Adaptive Biotechnologies Leadership Team
Elected by the shareholders, the Adaptive Biotechnologies' board of directors comprises two types of representatives: Adaptive Biotechnologies inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Adaptive. The board's role is to monitor Adaptive Biotechnologies' management team and ensure that shareholders' interests are well served. Adaptive Biotechnologies' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Adaptive Biotechnologies' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Yi Zhou, Chief Officer | ||
| Ronald Taylor, Independent Director | ||
| Ricardo Martinez, Chief Medical Officer | ||
| Dean Schorno, CFO | ||
| Nancy Hill, Senior Vice President General Manager - Research Products | ||
| Daniel Rosenberg, Director | ||
| Stacy Taylor, General VP | ||
| Stephen Mengert, Director | ||
| Gregory Scott, Independent Director | ||
| Mark Adams, Chief Officer | ||
| Julie Rubinstein, President COO | ||
| Francis Lo, Chief Officer | ||
| Sharon Benzeno, Chief Medicine | ||
| Andrew Jordan, Chief Marketing Officer | ||
| Chad MBA, CEO CoFounder | ||
| Nitin Sood, Chief MRD | ||
| Graham Cherrington, Pres and COO | ||
| Thomas Hall, Chairman and CEO | ||
| Jeffery Vender, Independent Director | ||
| Steven Napolitano, Independent Director | ||
| Tycho Peterson, Chief Officer | ||
| Harlan Robins, Co-Founder, Chief Scientific Officer | ||
| Kyle Piskel, Principal Officer | ||
| James Muzzarelli, Executive Medical Director | ||
| Frank Williams, CFO, Executive Vice President | ||
| Susan Bobulsky, Chief MRD | ||
| Richard Covert, Chairman of the Board | ||
| Chad Robins, President CEO, Co-Founder | ||
| Willis, Senior Vice President General Manager - Diagnostic Products | ||
| Karina Calzadilla, Vice Relations | ||
| Timothy Fielding, CFO and Treasurer | ||
| MBA MBA, CEO CoFounder | ||
| Traci Bowen, Sr. VP of HR | ||
| Christopher Carlson, Founder |
Adaptive Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Adaptive Biotechnologies a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.58 | ||||
| Return On Asset | -0.17 | ||||
| Profit Margin | (1.32) % | ||||
| Operating Margin | (1.00) % | ||||
| Current Valuation | 257.25 M | ||||
| Shares Outstanding | 145.09 M | ||||
| Shares Owned By Insiders | 2.80 % | ||||
| Shares Owned By Institutions | 95.84 % | ||||
| Number Of Shares Shorted | 9.1 M | ||||
| Price To Earning | 0.25 X |
Pair Trading with Adaptive Biotechnologies
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Adaptive Biotechnologies position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Adaptive Biotechnologies will appreciate offsetting losses from the drop in the long position's value.Moving together with Adaptive Stock
| 0.76 | KA | Kineta Inc Financial Report 9th of May 2024 | PairCorr |
| 0.74 | DRMA | Dermata Therapeutics Financial Report 9th of May 2024 | PairCorr |
Moving against Adaptive Stock
| 0.87 | YS | YS Biopharma | PairCorr |
| 0.82 | FUSN | Fusion PharmaceuticalsInc Financial Report 9th of May 2024 | PairCorr |
| 0.8 | DSGN | Design Therapeutics Financial Report 14th of May 2024 | PairCorr |
| 0.78 | ACB | Aurora Cannabis Trending | PairCorr |
| 0.78 | XFOR | X4 Pharmaceuticals Earnings Call Next Week | PairCorr |
The ability to find closely correlated positions to Adaptive Biotechnologies could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Adaptive Biotechnologies when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Adaptive Biotechnologies - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Adaptive Biotechnologies Corp to buy it.
The correlation of Adaptive Biotechnologies is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Adaptive Biotechnologies moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Adaptive Biotechnologies moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Adaptive Biotechnologies can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adaptive Biotechnologies Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Complementary Tools for Adaptive Stock analysis
When running Adaptive Biotechnologies' price analysis, check to measure Adaptive Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptive Biotechnologies is operating at the current time. Most of Adaptive Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Adaptive Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptive Biotechnologies' price. Additionally, you may evaluate how the addition of Adaptive Biotechnologies to your portfolios can decrease your overall portfolio volatility.
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |
Is Adaptive Biotechnologies' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adaptive Biotechnologies. If investors know Adaptive will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adaptive Biotechnologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.56) | Revenue Per Share 1.179 | Quarterly Revenue Growth (0.17) | Return On Assets (0.17) | Return On Equity (0.58) |
The market value of Adaptive Biotechnologies is measured differently than its book value, which is the value of Adaptive that is recorded on the company's balance sheet. Investors also form their own opinion of Adaptive Biotechnologies' value that differs from its market value or its book value, called intrinsic value, which is Adaptive Biotechnologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adaptive Biotechnologies' market value can be influenced by many factors that don't directly affect Adaptive Biotechnologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adaptive Biotechnologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Adaptive Biotechnologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adaptive Biotechnologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.